CHE seminar - Optimal screening strategies for pre-symptomatic childhood type 1 diabetes in the United States

Event details

Abstract:

Pre-symptomatic type 1 diabetes screening, monitoring, and education for children and adolescents can prevent serious diabetic ketoacidosis events at diagnosis. Factors identifying risk for type 1 diabetes are numerous and lead to thousands of screening combinations across age and frequency, among other factors. There is resistance from payers in the United States to expand coverage and reimbursement to general population screening given the low incidence and prevalence of type 1 diabetes. Combining robust optimisation and existing patient-level diabetes modeling approaches, we identified a set of feasible and optimal strategies to generate a range of potential health benefits at various levels of health spending. A discussion will follow on global implications of expanding screening, including recent efforts in the United Kingdom.

If you are not a member of University of York staff and are interested in attending a seminar, please contact adrian.villasenor-lopez@york.ac.uk or dacheng.huo@york.ac.uk so that we can ensure we have sufficient space. Please also use these contacts if you wish to be added to the mailing list.

About the speaker

R. Brett McQueen

R. Brett McQueen is Director for the Center for Pharmaceutical Value (pValue) at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences (CU-SSPSS), where he is also an Associate Professor in the Department of Clinical Pharmacy. His funded work includes decision modeling applications, multi-criteria decision analysis (MCDA), outcomes-based outcomes contracting, and patient preferences research. He is active in ISPOR and other health-economics professional societies through contributions to short courses, workshops, issue panels, and research presentations.